Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Get Free Report) insider Hendrik Scholl sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $165.99, for a total value of $331,980.00. Following the completion of the transaction, the insider directly owned 12,500 shares in the company, valued at approximately $2,074,875. The trade was a 13.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Hendrik Peter Scholl also recently made the following trade(s):
- On Thursday, October 1st, Hendrik Scholl sold 500 shares of Belite Bio stock. The shares were sold at an average price of $165.32, for a total value of $82,660.00.
Belite Bio Trading Down 1.1%
BLTE stock opened at $162.56 on Tuesday. The firm has a 50 day simple moving average of $160.26 and a 200-day simple moving average of $160.22. The company has a market capitalization of $6.55 billion, a P/E ratio of -59.55 and a beta of -1.19. Belite Bio, Inc. Sponsored ADR has a twelve month low of $105.88 and a twelve month high of $200.00.
Belite Bio (NASDAQ:BLTE – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.19. On average, research analysts predict that Belite Bio, Inc. Sponsored ADR will post -3.08 EPS for the current year.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on BLTE shares. Zacks Research downgraded shares of Belite Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 18th. HC Wainwright reaffirmed a “buy” rating and set a $245.00 price target on shares of Belite Bio in a research report on Thursday, October 15th. Benchmark reaffirmed a “buy” rating on shares of Belite Bio in a research report on Friday, August 14th. Cantor Fitzgerald lifted their price target on Belite Bio from $266.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Finally, Canaccord Genuity Group boosted their price objective on Belite Bio from $303.00 to $314.00 and gave the company a “buy” rating in a report on Monday. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $226.91.
Check Out Our Latest Stock Analysis on Belite Bio
Hedge Funds Weigh In On Belite Bio
A number of hedge funds have recently added to or reduced their stakes in the business. Great Point Partners LLC acquired a new position in shares of Belite Bio in the 3rd quarter valued at about $12,736,000. Marshall Wace LLP acquired a new position in Belite Bio during the 3rd quarter valued at approximately $15,282,000. State Street Corp boosted its position in Belite Bio by 6.9% during the 3rd quarter. State Street Corp now owns 34,044 shares of the company’s stock valued at $5,781,000 after purchasing an additional 2,196 shares during the period. Alberta Investment Management Corp acquired a new position in Belite Bio during the 3rd quarter valued at approximately $4,076,000. Finally, Candriam S.C.A. bought a new position in Belite Bio during the 3rd quarter worth $10,711,000. Institutional investors and hedge funds own 0.53% of the company’s stock.
Belite Bio Company Profile
Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.
Featured Articles
- Five stocks we like better than Belite Bio
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.
